What Halozyme Therapeutics Shareholders Got Right

If you only glanced at Halozyme Therapeutics headlines in 2026, the steady stream of royalty wins, court victories, and collaboration deals might have blended into the usual biotech noise. Holding Halozyme Therapeutics from the start of the year would have returned 44.6%, including dividends. If you had been weighing those mixed analyst targets from late 2025, what exactly in the record back then justified taking that kind of risk on a concentrated royalty engine?

The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.

Halozyme Therapeutics has already moved. Pinpoint other ways to investigate the theme among 36 healthcare AI stocks.

The Argument You Would Have Been Weighing Up On Halozyme Therapeutics

The shares cost US$67.3 at the start of the period, and the argument around Halozyme Therapeutics split into two reasonable stories rather than one clear answer.

The bullish December 2025 Narrative saw Fair Value at US$71.67, 6% above the start price. This view hinged on assumptions of 18.7% annual revenue growth and profit margins reaching 54.2% over three years.

The bearish May 2025 case pinned Fair Value at US$49.57, 26% below the start price. This perspective stressed heavy reliance on ENHANZE and the risk that patent expiries and pricing pressure could erode future royalty economics.

What The 2026 Evidence Did To The Halozyme Therapeutics Argument

Halozyme Therapeutics posted Q3 2026 revenue of US$492.974 million and net income of US$247.049 million, with net margin edging up to 50.1%. That outcome generally leaned toward the bullish narrative that focused on high margin royalties. However, the need for a US$1.3 billion convertible notes deal and insider selling kept the cautious view on risk and potential future dilution relevant.

The useful takeaway is clear: when a story hinges on rich, durable royalties, it can be helpful to watch reported margins and new licensing deals, not just headline revenue, to see whether the thesis is actually playing out.

What You Are Paying For In Halozyme Therapeutics After A 45% Run

Halozyme Therapeutics now trades at US$102, after a 44.6% gain from the start of the year, while the bearish analyst Narrative on Simply Wall St places its Fair Value below that market price.

That view leans on concern that ENHANZE and Hypercon must support rich royalties for a long time. Anyone buying today is effectively assuming those platforms keep winning deals, even if rival enzymes pressure pricing and partner choices.

"Although Halozyme Therapeutics is adding ENHANZE programs and has guided to future launches that could support royalties into the 2030s, credible alternatives such as Alteogen’s ALT-B4 now give large pharma negotiating leverage that can cap royalty rates and limit the revenue uplift currently embedded in long-term forecasts."

That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for

Before The Next Story Makes Headlines

You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.

• Company 1 - 32% below our estimate - uses a pending bank acquisition and deposit funding shift to rewire its lending model.
• Company 2 - 31% below our estimate - turns a backlog of AI infrastructure and multicloud database contracts into growing subscription-based revenue streams.
• Company 3 - 25% below our estimate - builds new manufacturing and logistics routes to support higher margin film and service offerings.

Those are three of them. See every one of the 32 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com